Evidence map›Paper›PMID 37239457›Full record

ArticleGenes2023

Transcription of

Natella I Enukashvily, Liubov A Belik, Natalia Yu Semenova, Ivan I Kostroma, Ekaterina V Motyko, Sergey V Gritsaev, Stanislav S Bessmeltsev, Sergey V Sidorkevich, Irina S Martynkevich

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Natella I EnukashvilyRussian Research Institute of Hematology and Transfusiology, FMBA of Russian Federation, 191024 St. Petersburg, Russia.ORCID 0000-0002-5971-7917
Liubov A BelikRussian Research Institute of Hematology and Transfusiology, FMBA of Russian Federation, 191024 St. Petersburg, Russia.ORCID 0000-0002-4589-8702
Natalia Yu SemenovaRussian Research Institute of Hematology and Transfusiology, FMBA of Russian Federation, 191024 St. Petersburg, Russia.ORCID 0000-0003-4069-0678
Ivan I KostromaRussian Research Institute of Hematology and Transfusiology, FMBA of Russian Federation, 191024 St. Petersburg, Russia.ORCID 0000-0003-3768-0831
Ekaterina V MotykoRussian Research Institute of Hematology and Transfusiology, FMBA of Russian Federation, 191024 St. Petersburg, Russia.
Sergey V GritsaevRussian Research Institute of Hematology and Transfusiology, FMBA of Russian Federation, 191024 St. Petersburg, Russia.ORCID 0000-0001-7586-4709
Stanislav S BessmeltsevRussian Research Institute of Hematology and Transfusiology, FMBA of Russian Federation, 191024 St. Petersburg, Russia.
Sergey V SidorkevichRussian Research Institute of Hematology and Transfusiology, FMBA of Russian Federation, 191024 St. Petersburg, Russia.
Irina S MartynkevichRussian Research Institute of Hematology and Transfusiology, FMBA of Russian Federation, 191024 St. Petersburg, Russia.
State Research Institute of Highly Pure Biopreparations · RUInstitute of Cytology · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stromal cells (MSCs) are involved in bone tissue remodeling due to their ability to differentiate into osteoblasts and to influence osteoclasts' activity. Multiple myeloma (MM) is associated with bone resorption. During disease progression, MSCs acquire a tumor-associated phenotype, losing their osteogenic potential. The process is associated with impaired osteoblasts/osteoclasts balance. The WNT signaling pathway plays a major role in maintaining the balance. In MM, it functions in an aberrant way. It is not known yet whether the WNT pathway is restored in patients' bone narrow after treatment. The aim of the study was to compare the level of

Indexed as

Mesenchymal Stem CellsMultiple Myelomabeta CateninCell DifferentiationHumansRNA, MessengerWnt Signaling Pathwaybeta CateninRNA, Messengerhematopoietic nichemesenchymal stromal cellsmultiple myelomaprognostic markersWNT signaling

Identifiers

PMID37239457
PMCPMC10218155
OpenAlexW4377041267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.